nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefenamic acid—PTGS2—bone cancer	0.435	1	CbGaD
Mefenamic acid—AKR1C3—Doxorubicin—bone cancer	0.308	0.755	CbGbCtD
Mefenamic acid—PTGS2—Cisplatin—bone cancer	0.0744	0.183	CbGbCtD
Mefenamic acid—CYP2C9—Cisplatin—bone cancer	0.0253	0.0621	CbGbCtD
Mefenamic acid—AKR1C2—Benzo(a)pyrene metabolism—CYP3A4—bone cancer	0.00761	0.141	CbGpPWpGaD
Mefenamic acid—AKR1C1—Benzo(a)pyrene metabolism—CYP3A4—bone cancer	0.00559	0.103	CbGpPWpGaD
Mefenamic acid—AKR1C3—Benzo(a)pyrene metabolism—CYP3A4—bone cancer	0.00376	0.0695	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metapathway biotransformation—CYP4V2—bone cancer	0.00358	0.0662	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metapathway biotransformation—CYP4V2—bone cancer	0.00263	0.0486	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metapathway biotransformation—CYP4V2—bone cancer	0.00177	0.0327	CbGpPWpGaD
Mefenamic acid—Acetylsalicylic acid—TP53—bone cancer	0.00148	0.225	CrCbGaD
Mefenamic acid—AKR1C3—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.00117	0.0216	CbGpPWpGaD
Mefenamic acid—CYP2C8—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00116	0.0214	CbGpPWpGaD
Mefenamic acid—CYP2C8—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.00111	0.0204	CbGpPWpGaD
Mefenamic acid—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000941	0.0174	CbGpPWpGaD
Mefenamic acid—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.0009	0.0166	CbGpPWpGaD
Mefenamic acid—Floctafenine—PTGS2—bone cancer	0.000758	0.116	CrCbGaD
Mefenamic acid—AKR1C2—Metapathway biotransformation—CYP3A4—bone cancer	0.000709	0.0131	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metapathway biotransformation—GSTP1—bone cancer	0.000606	0.0112	CbGpPWpGaD
Mefenamic acid—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000558	0.0103	CbGpPWpGaD
Mefenamic acid—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000537	0.00992	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metapathway biotransformation—CYP3A4—bone cancer	0.00052	0.00961	CbGpPWpGaD
Mefenamic acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—bone cancer	0.00051	0.00942	CbGpPWpGaD
Mefenamic acid—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.000509	0.00941	CbGpPWpGaD
Mefenamic acid—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000509	0.0094	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000498	0.0092	CbGpPWpGaD
Mefenamic acid—Lumiracoxib—PTGS2—bone cancer	0.000489	0.0746	CrCbGaD
Mefenamic acid—Tiaprofenic acid—PTGS2—bone cancer	0.000489	0.0746	CrCbGaD
Mefenamic acid—Nepafenac—PTGS2—bone cancer	0.000465	0.071	CrCbGaD
Mefenamic acid—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000454	0.00839	CbGpPWpGaD
Mefenamic acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.00045	0.00831	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metapathway biotransformation—GSTP1—bone cancer	0.000445	0.00822	CbGpPWpGaD
Mefenamic acid—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000437	0.00807	CbGpPWpGaD
Mefenamic acid—Niflumic Acid—PTGS2—bone cancer	0.000435	0.0665	CrCbGaD
Mefenamic acid—AKR1C2—Metabolism—NDUFA12—bone cancer	0.000431	0.00796	CbGpPWpGaD
Mefenamic acid—AKR1C3—Arachidonic acid metabolism—PTGS2—bone cancer	0.000423	0.00781	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000405	0.00749	CbGpPWpGaD
Mefenamic acid—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000399	0.00737	CbGpPWpGaD
Mefenamic acid—Salsalate—PTGS2—bone cancer	0.000386	0.059	CrCbGaD
Mefenamic acid—Meclofenamic acid—PTGS2—bone cancer	0.000381	0.0581	CrCbGaD
Mefenamic acid—AKR1C2—Metabolism—NT5C3A—bone cancer	0.000357	0.0066	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metapathway biotransformation—CYP3A4—bone cancer	0.00035	0.00647	CbGpPWpGaD
Mefenamic acid—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000331	0.00611	CbGpPWpGaD
Mefenamic acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.00033	0.00609	CbGpPWpGaD
Mefenamic acid—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000328	0.00605	CbGpPWpGaD
Mefenamic acid—Fenoprofen—PTGS2—bone cancer	0.000319	0.0487	CrCbGaD
Mefenamic acid—AKR1C1—Metabolism—NDUFA12—bone cancer	0.000316	0.00584	CbGpPWpGaD
Mefenamic acid—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000312	0.00576	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metapathway biotransformation—GSTP1—bone cancer	0.000299	0.00553	CbGpPWpGaD
Mefenamic acid—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000297	0.00549	CbGpPWpGaD
Mefenamic acid—Gastrointestinal haemorrhage—Epirubicin—bone cancer	0.000297	0.00305	CcSEcCtD
Mefenamic acid—Anxiety—Cisplatin—bone cancer	0.000295	0.00303	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000294	0.00302	CcSEcCtD
Mefenamic acid—Liver function test abnormal—Methotrexate—bone cancer	0.000293	0.00301	CcSEcCtD
Mefenamic acid—Discomfort—Cisplatin—bone cancer	0.000293	0.00301	CcSEcCtD
Mefenamic acid—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000291	0.00537	CbGpPWpGaD
Mefenamic acid—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000291	0.00299	CcSEcCtD
Mefenamic acid—Acetylsalicylic acid—PTGS2—bone cancer	0.000288	0.044	CrCbGaD
Mefenamic acid—Renal impairment—Doxorubicin—bone cancer	0.000288	0.00296	CcSEcCtD
Mefenamic acid—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000285	0.00293	CcSEcCtD
Mefenamic acid—Purpura—Doxorubicin—bone cancer	0.000285	0.00293	CcSEcCtD
Mefenamic acid—Oedema—Cisplatin—bone cancer	0.000284	0.00292	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Cisplatin—bone cancer	0.000284	0.00292	CcSEcCtD
Mefenamic acid—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000284	0.00291	CcSEcCtD
Mefenamic acid—Infection—Cisplatin—bone cancer	0.000282	0.0029	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Cisplatin—bone cancer	0.000278	0.00286	CcSEcCtD
Mefenamic acid—Tachycardia—Cisplatin—bone cancer	0.000277	0.00285	CcSEcCtD
Mefenamic acid—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000277	0.00511	CbGpPWpGaD
Mefenamic acid—Skin disorder—Cisplatin—bone cancer	0.000276	0.00283	CcSEcCtD
Mefenamic acid—Hyponatraemia—Doxorubicin—bone cancer	0.000276	0.00283	CcSEcCtD
Mefenamic acid—Gastrointestinal haemorrhage—Doxorubicin—bone cancer	0.000274	0.00282	CcSEcCtD
Mefenamic acid—Asthma—Methotrexate—bone cancer	0.000274	0.00281	CcSEcCtD
Mefenamic acid—Liver function test abnormal—Epirubicin—bone cancer	0.000274	0.00281	CcSEcCtD
Mefenamic acid—Eosinophilia—Methotrexate—bone cancer	0.000271	0.00279	CcSEcCtD
Mefenamic acid—Anorexia—Cisplatin—bone cancer	0.000271	0.00278	CcSEcCtD
Mefenamic acid—Pancreatitis—Methotrexate—bone cancer	0.000269	0.00276	CcSEcCtD
Mefenamic acid—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000267	0.00274	CcSEcCtD
Mefenamic acid—Hypotension—Cisplatin—bone cancer	0.000265	0.00273	CcSEcCtD
Mefenamic acid—Gastritis—Epirubicin—bone cancer	0.000262	0.0027	CcSEcCtD
Mefenamic acid—AKR1C1—Metabolism—NT5C3A—bone cancer	0.000262	0.00484	CbGpPWpGaD
Mefenamic acid—Pancytopenia—Methotrexate—bone cancer	0.00026	0.00267	CcSEcCtD
Mefenamic acid—Asthma—Epirubicin—bone cancer	0.000256	0.00263	CcSEcCtD
Mefenamic acid—Dysuria—Methotrexate—bone cancer	0.000256	0.00263	CcSEcCtD
Mefenamic acid—Paraesthesia—Cisplatin—bone cancer	0.000255	0.00262	CcSEcCtD
Mefenamic acid—Eosinophilia—Epirubicin—bone cancer	0.000254	0.00261	CcSEcCtD
Mefenamic acid—Liver function test abnormal—Doxorubicin—bone cancer	0.000253	0.0026	CcSEcCtD
Mefenamic acid—Dyspnoea—Cisplatin—bone cancer	0.000253	0.0026	CcSEcCtD
Mefenamic acid—Pancreatitis—Epirubicin—bone cancer	0.000251	0.00258	CcSEcCtD
Mefenamic acid—Photosensitivity reaction—Methotrexate—bone cancer	0.00025	0.00257	CcSEcCtD
Mefenamic acid—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.00025	0.00461	CbGpPWpGaD
Mefenamic acid—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.000247	0.00254	CcSEcCtD
Mefenamic acid—Decreased appetite—Cisplatin—bone cancer	0.000247	0.00254	CcSEcCtD
Mefenamic acid—Pneumonia—Methotrexate—bone cancer	0.000246	0.00252	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Cisplatin—bone cancer	0.000245	0.00252	CcSEcCtD
Mefenamic acid—Drowsiness—Methotrexate—bone cancer	0.000244	0.00251	CcSEcCtD
Mefenamic acid—Pancytopenia—Epirubicin—bone cancer	0.000243	0.0025	CcSEcCtD
Mefenamic acid—Gastritis—Doxorubicin—bone cancer	0.000243	0.0025	CcSEcCtD
Mefenamic acid—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000242	0.00249	CcSEcCtD
Mefenamic acid—Renal failure—Methotrexate—bone cancer	0.00024	0.00247	CcSEcCtD
Mefenamic acid—Dysuria—Epirubicin—bone cancer	0.00024	0.00246	CcSEcCtD
Mefenamic acid—Stomatitis—Methotrexate—bone cancer	0.000238	0.00245	CcSEcCtD
Mefenamic acid—Salicylic acid—PTGS2—bone cancer	0.000238	0.0363	CrCbGaD
Mefenamic acid—Conjunctivitis—Methotrexate—bone cancer	0.000237	0.00244	CcSEcCtD
Mefenamic acid—Asthma—Doxorubicin—bone cancer	0.000237	0.00244	CcSEcCtD
Mefenamic acid—Eosinophilia—Doxorubicin—bone cancer	0.000235	0.00241	CcSEcCtD
Mefenamic acid—Photosensitivity reaction—Epirubicin—bone cancer	0.000234	0.0024	CcSEcCtD
Mefenamic acid—Feeling abnormal—Cisplatin—bone cancer	0.000234	0.0024	CcSEcCtD
Mefenamic acid—Haematuria—Methotrexate—bone cancer	0.000233	0.00239	CcSEcCtD
Mefenamic acid—Pancreatitis—Doxorubicin—bone cancer	0.000233	0.00239	CcSEcCtD
Mefenamic acid—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000232	0.00428	CbGpPWpGaD
Mefenamic acid—Hyperglycaemia—Epirubicin—bone cancer	0.000231	0.00238	CcSEcCtD
Mefenamic acid—Pneumonia—Epirubicin—bone cancer	0.00023	0.00236	CcSEcCtD
Mefenamic acid—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000229	0.00423	CbGpPWpGaD
Mefenamic acid—Drowsiness—Epirubicin—bone cancer	0.000229	0.00235	CcSEcCtD
Mefenamic acid—Agranulocytosis—Methotrexate—bone cancer	0.000228	0.00234	CcSEcCtD
Mefenamic acid—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000227	0.00233	CcSEcCtD
Mefenamic acid—Pancytopenia—Doxorubicin—bone cancer	0.000225	0.00231	CcSEcCtD
Mefenamic acid—Renal failure—Epirubicin—bone cancer	0.000225	0.00231	CcSEcCtD
Mefenamic acid—Body temperature increased—Cisplatin—bone cancer	0.000224	0.00231	CcSEcCtD
Mefenamic acid—Jaundice—Epirubicin—bone cancer	0.000223	0.00229	CcSEcCtD
Mefenamic acid—Stomatitis—Epirubicin—bone cancer	0.000223	0.00229	CcSEcCtD
Mefenamic acid—Conjunctivitis—Epirubicin—bone cancer	0.000222	0.00228	CcSEcCtD
Mefenamic acid—Dysuria—Doxorubicin—bone cancer	0.000222	0.00228	CcSEcCtD
Mefenamic acid—Haemoglobin—Methotrexate—bone cancer	0.00022	0.00226	CcSEcCtD
Mefenamic acid—Hepatitis—Methotrexate—bone cancer	0.000219	0.00225	CcSEcCtD
Mefenamic acid—Haemorrhage—Methotrexate—bone cancer	0.000219	0.00225	CcSEcCtD
Mefenamic acid—Haematuria—Epirubicin—bone cancer	0.000218	0.00224	CcSEcCtD
Mefenamic acid—Diclofenac—CYP3A4—bone cancer	0.000217	0.0332	CrCbGaD
Mefenamic acid—Urinary tract disorder—Methotrexate—bone cancer	0.000217	0.00223	CcSEcCtD
Mefenamic acid—Photosensitivity reaction—Doxorubicin—bone cancer	0.000217	0.00222	CcSEcCtD
Mefenamic acid—Urethral disorder—Methotrexate—bone cancer	0.000215	0.00221	CcSEcCtD
Mefenamic acid—Hyperglycaemia—Doxorubicin—bone cancer	0.000214	0.0022	CcSEcCtD
Mefenamic acid—Agranulocytosis—Epirubicin—bone cancer	0.000213	0.00219	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism—NDUFA12—bone cancer	0.000213	0.00393	CbGpPWpGaD
Mefenamic acid—Pneumonia—Doxorubicin—bone cancer	0.000213	0.00219	CcSEcCtD
Mefenamic acid—Diclofenac—PTGS2—bone cancer	0.000213	0.0325	CrCbGaD
Mefenamic acid—Drowsiness—Doxorubicin—bone cancer	0.000211	0.00217	CcSEcCtD
Mefenamic acid—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.00021	0.00215	CcSEcCtD
Mefenamic acid—Flurbiprofen—PTGS2—bone cancer	0.000208	0.0318	CrCbGaD
Mefenamic acid—Renal failure—Doxorubicin—bone cancer	0.000208	0.00214	CcSEcCtD
Mefenamic acid—Erythema multiforme—Methotrexate—bone cancer	0.000207	0.00213	CcSEcCtD
Mefenamic acid—Haemoglobin—Epirubicin—bone cancer	0.000206	0.00212	CcSEcCtD
Mefenamic acid—Jaundice—Doxorubicin—bone cancer	0.000206	0.00212	CcSEcCtD
Mefenamic acid—Stomatitis—Doxorubicin—bone cancer	0.000206	0.00212	CcSEcCtD
Mefenamic acid—Conjunctivitis—Doxorubicin—bone cancer	0.000206	0.00211	CcSEcCtD
Mefenamic acid—Haemorrhage—Epirubicin—bone cancer	0.000205	0.00211	CcSEcCtD
Mefenamic acid—Hepatitis—Epirubicin—bone cancer	0.000205	0.00211	CcSEcCtD
Mefenamic acid—Tinnitus—Methotrexate—bone cancer	0.000204	0.0021	CcSEcCtD
Mefenamic acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	0.000204	0.00378	CbGpPWpGaD
Mefenamic acid—Asthenia—Cisplatin—bone cancer	0.000204	0.00209	CcSEcCtD
Mefenamic acid—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	0.000204	0.00376	CbGpPWpGaD
Mefenamic acid—Urinary tract disorder—Epirubicin—bone cancer	0.000203	0.00208	CcSEcCtD
Mefenamic acid—Haematuria—Doxorubicin—bone cancer	0.000202	0.00207	CcSEcCtD
Mefenamic acid—Urethral disorder—Epirubicin—bone cancer	0.000201	0.00207	CcSEcCtD
Mefenamic acid—Agranulocytosis—Doxorubicin—bone cancer	0.000197	0.00203	CcSEcCtD
Mefenamic acid—Diarrhoea—Cisplatin—bone cancer	0.000194	0.002	CcSEcCtD
Mefenamic acid—Erythema multiforme—Epirubicin—bone cancer	0.000194	0.00199	CcSEcCtD
Mefenamic acid—Alopecia—Methotrexate—bone cancer	0.000194	0.00199	CcSEcCtD
Mefenamic acid—Mental disorder—Methotrexate—bone cancer	0.000192	0.00197	CcSEcCtD
Mefenamic acid—Tinnitus—Epirubicin—bone cancer	0.000191	0.00197	CcSEcCtD
Mefenamic acid—Haemoglobin—Doxorubicin—bone cancer	0.000191	0.00196	CcSEcCtD
Mefenamic acid—PTGS2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.00019	0.00351	CbGpPWpGaD
Mefenamic acid—Haemorrhage—Doxorubicin—bone cancer	0.00019	0.00195	CcSEcCtD
Mefenamic acid—Hepatitis—Doxorubicin—bone cancer	0.00019	0.00195	CcSEcCtD
Mefenamic acid—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000189	0.00349	CbGpPWpGaD
Mefenamic acid—Ketoprofen—PTGS2—bone cancer	0.000188	0.0288	CrCbGaD
Mefenamic acid—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000188	0.00347	CbGpPWpGaD
Mefenamic acid—Urinary tract disorder—Doxorubicin—bone cancer	0.000187	0.00193	CcSEcCtD
Mefenamic acid—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000186	0.00344	CbGpPWpGaD
Mefenamic acid—Urethral disorder—Doxorubicin—bone cancer	0.000186	0.00191	CcSEcCtD
Mefenamic acid—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000184	0.0034	CbGpPWpGaD
Mefenamic acid—Arrhythmia—Epirubicin—bone cancer	0.000183	0.00188	CcSEcCtD
Mefenamic acid—Alopecia—Epirubicin—bone cancer	0.000181	0.00186	CcSEcCtD
Mefenamic acid—Vomiting—Cisplatin—bone cancer	0.00018	0.00185	CcSEcCtD
Mefenamic acid—Vision blurred—Methotrexate—bone cancer	0.00018	0.00185	CcSEcCtD
Mefenamic acid—Mental disorder—Epirubicin—bone cancer	0.00018	0.00185	CcSEcCtD
Mefenamic acid—Erythema multiforme—Doxorubicin—bone cancer	0.00018	0.00184	CcSEcCtD
Mefenamic acid—Rash—Cisplatin—bone cancer	0.000179	0.00184	CcSEcCtD
Mefenamic acid—Dermatitis—Cisplatin—bone cancer	0.000179	0.00184	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Methotrexate—bone cancer	0.000177	0.00182	CcSEcCtD
Mefenamic acid—Tinnitus—Doxorubicin—bone cancer	0.000177	0.00182	CcSEcCtD
Mefenamic acid—Anaemia—Methotrexate—bone cancer	0.000176	0.00181	CcSEcCtD
Mefenamic acid—AKR1C3—Metabolism—NT5C3A—bone cancer	0.000176	0.00326	CbGpPWpGaD
Mefenamic acid—Flatulence—Epirubicin—bone cancer	0.000176	0.00181	CcSEcCtD
Mefenamic acid—Tension—Epirubicin—bone cancer	0.000175	0.0018	CcSEcCtD
Mefenamic acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000175	0.00324	CbGpPWpGaD
Mefenamic acid—Nervousness—Epirubicin—bone cancer	0.000173	0.00178	CcSEcCtD
Mefenamic acid—Malaise—Methotrexate—bone cancer	0.000172	0.00177	CcSEcCtD
Mefenamic acid—Vertigo—Methotrexate—bone cancer	0.000171	0.00176	CcSEcCtD
Mefenamic acid—Leukopenia—Methotrexate—bone cancer	0.000171	0.00176	CcSEcCtD
Mefenamic acid—Arrhythmia—Doxorubicin—bone cancer	0.00017	0.00174	CcSEcCtD
Mefenamic acid—Nausea—Cisplatin—bone cancer	0.000169	0.00173	CcSEcCtD
Mefenamic acid—Vision blurred—Epirubicin—bone cancer	0.000168	0.00173	CcSEcCtD
Mefenamic acid—Alopecia—Doxorubicin—bone cancer	0.000168	0.00172	CcSEcCtD
Mefenamic acid—Mental disorder—Doxorubicin—bone cancer	0.000166	0.00171	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Epirubicin—bone cancer	0.000166	0.0017	CcSEcCtD
Mefenamic acid—Convulsion—Methotrexate—bone cancer	0.000165	0.0017	CcSEcCtD
Mefenamic acid—Anaemia—Epirubicin—bone cancer	0.000165	0.0017	CcSEcCtD
Mefenamic acid—Flatulence—Doxorubicin—bone cancer	0.000163	0.00167	CcSEcCtD
Mefenamic acid—Tension—Doxorubicin—bone cancer	0.000162	0.00167	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000161	0.00166	CcSEcCtD
Mefenamic acid—Malaise—Epirubicin—bone cancer	0.000161	0.00166	CcSEcCtD
Mefenamic acid—Discomfort—Methotrexate—bone cancer	0.000161	0.00165	CcSEcCtD
Mefenamic acid—Nervousness—Doxorubicin—bone cancer	0.000161	0.00165	CcSEcCtD
Mefenamic acid—Vertigo—Epirubicin—bone cancer	0.00016	0.00165	CcSEcCtD
Mefenamic acid—Syncope—Epirubicin—bone cancer	0.00016	0.00165	CcSEcCtD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.00016	0.00296	CbGpPWpGaD
Mefenamic acid—Leukopenia—Epirubicin—bone cancer	0.00016	0.00164	CcSEcCtD
Mefenamic acid—Palpitations—Epirubicin—bone cancer	0.000158	0.00162	CcSEcCtD
Mefenamic acid—Confusional state—Methotrexate—bone cancer	0.000157	0.00161	CcSEcCtD
Mefenamic acid—Loss of consciousness—Epirubicin—bone cancer	0.000157	0.00161	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism—ENO2—bone cancer	0.000156	0.00289	CbGpPWpGaD
Mefenamic acid—Anaphylactic shock—Methotrexate—bone cancer	0.000156	0.0016	CcSEcCtD
Mefenamic acid—Vision blurred—Doxorubicin—bone cancer	0.000156	0.0016	CcSEcCtD
Mefenamic acid—Convulsion—Epirubicin—bone cancer	0.000155	0.00159	CcSEcCtD
Mefenamic acid—Infection—Methotrexate—bone cancer	0.000155	0.00159	CcSEcCtD
Mefenamic acid—PTGS1—Biological oxidations—CYP3A4—bone cancer	0.000155	0.00286	CbGpPWpGaD
Mefenamic acid—Hypertension—Epirubicin—bone cancer	0.000154	0.00158	CcSEcCtD
Mefenamic acid—Ill-defined disorder—Doxorubicin—bone cancer	0.000153	0.00158	CcSEcCtD
Mefenamic acid—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000153	0.00283	CbGpPWpGaD
Mefenamic acid—Anaemia—Doxorubicin—bone cancer	0.000153	0.00157	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Methotrexate—bone cancer	0.000153	0.00157	CcSEcCtD
Mefenamic acid—Anxiety—Epirubicin—bone cancer	0.000152	0.00156	CcSEcCtD
Mefenamic acid—Skin disorder—Methotrexate—bone cancer	0.000151	0.00155	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000151	0.00155	CcSEcCtD
Mefenamic acid—Discomfort—Epirubicin—bone cancer	0.00015	0.00154	CcSEcCtD
Mefenamic acid—Malaise—Doxorubicin—bone cancer	0.000149	0.00153	CcSEcCtD
Mefenamic acid—AKR1C1—Signaling Pathways—RGS1—bone cancer	0.000149	0.00275	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—GRM4—bone cancer	0.000149	0.00275	CbGpPWpGaD
Mefenamic acid—Dry mouth—Epirubicin—bone cancer	0.000149	0.00153	CcSEcCtD
Mefenamic acid—Vertigo—Doxorubicin—bone cancer	0.000148	0.00153	CcSEcCtD
Mefenamic acid—Anorexia—Methotrexate—bone cancer	0.000148	0.00153	CcSEcCtD
Mefenamic acid—Syncope—Doxorubicin—bone cancer	0.000148	0.00152	CcSEcCtD
Mefenamic acid—Leukopenia—Doxorubicin—bone cancer	0.000148	0.00152	CcSEcCtD
Mefenamic acid—Confusional state—Epirubicin—bone cancer	0.000147	0.00151	CcSEcCtD
Mefenamic acid—Palpitations—Doxorubicin—bone cancer	0.000146	0.0015	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Epirubicin—bone cancer	0.000146	0.0015	CcSEcCtD
Mefenamic acid—Oedema—Epirubicin—bone cancer	0.000146	0.0015	CcSEcCtD
Mefenamic acid—Hypotension—Methotrexate—bone cancer	0.000146	0.0015	CcSEcCtD
Mefenamic acid—Loss of consciousness—Doxorubicin—bone cancer	0.000145	0.00149	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism—DHFR—bone cancer	0.000145	0.00268	CbGpPWpGaD
Mefenamic acid—Infection—Epirubicin—bone cancer	0.000145	0.00149	CcSEcCtD
Mefenamic acid—Shock—Epirubicin—bone cancer	0.000143	0.00147	CcSEcCtD
Mefenamic acid—Convulsion—Doxorubicin—bone cancer	0.000143	0.00147	CcSEcCtD
Mefenamic acid—Thrombocytopenia—Epirubicin—bone cancer	0.000143	0.00147	CcSEcCtD
Mefenamic acid—Hypertension—Doxorubicin—bone cancer	0.000143	0.00147	CcSEcCtD
Mefenamic acid—Tachycardia—Epirubicin—bone cancer	0.000142	0.00146	CcSEcCtD
Mefenamic acid—Skin disorder—Epirubicin—bone cancer	0.000142	0.00146	CcSEcCtD
Mefenamic acid—Insomnia—Methotrexate—bone cancer	0.000141	0.00145	CcSEcCtD
Mefenamic acid—Anxiety—Doxorubicin—bone cancer	0.00014	0.00144	CcSEcCtD
Mefenamic acid—Paraesthesia—Methotrexate—bone cancer	0.00014	0.00144	CcSEcCtD
Mefenamic acid—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.00014	0.00144	CcSEcCtD
Mefenamic acid—Discomfort—Doxorubicin—bone cancer	0.000139	0.00143	CcSEcCtD
Mefenamic acid—Anorexia—Epirubicin—bone cancer	0.000139	0.00143	CcSEcCtD
Mefenamic acid—Dyspnoea—Methotrexate—bone cancer	0.000139	0.00143	CcSEcCtD
Mefenamic acid—Somnolence—Methotrexate—bone cancer	0.000138	0.00142	CcSEcCtD
Mefenamic acid—Dry mouth—Doxorubicin—bone cancer	0.000138	0.00141	CcSEcCtD
Mefenamic acid—Dyspepsia—Methotrexate—bone cancer	0.000137	0.00141	CcSEcCtD
Mefenamic acid—AKR1C1—Disease—ENO2—bone cancer	0.000137	0.00253	CbGpPWpGaD
Mefenamic acid—Hypotension—Epirubicin—bone cancer	0.000136	0.0014	CcSEcCtD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000136	0.00251	CbGpPWpGaD
Mefenamic acid—Confusional state—Doxorubicin—bone cancer	0.000136	0.0014	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism—GNA11—bone cancer	0.000136	0.00251	CbGpPWpGaD
Mefenamic acid—Decreased appetite—Methotrexate—bone cancer	0.000135	0.00139	CcSEcCtD
Mefenamic acid—Anaphylactic shock—Doxorubicin—bone cancer	0.000135	0.00139	CcSEcCtD
Mefenamic acid—Oedema—Doxorubicin—bone cancer	0.000135	0.00139	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Methotrexate—bone cancer	0.000134	0.00138	CcSEcCtD
Mefenamic acid—Infection—Doxorubicin—bone cancer	0.000134	0.00138	CcSEcCtD
Mefenamic acid—Shock—Doxorubicin—bone cancer	0.000133	0.00136	CcSEcCtD
Mefenamic acid—PTGS1—Biological oxidations—GSTP1—bone cancer	0.000132	0.00244	CbGpPWpGaD
Mefenamic acid—Thrombocytopenia—Doxorubicin—bone cancer	0.000132	0.00136	CcSEcCtD
Mefenamic acid—Insomnia—Epirubicin—bone cancer	0.000132	0.00135	CcSEcCtD
Mefenamic acid—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	0.000132	0.00243	CbGpPWpGaD
Mefenamic acid—Tachycardia—Doxorubicin—bone cancer	0.000132	0.00135	CcSEcCtD
Mefenamic acid—Skin disorder—Doxorubicin—bone cancer	0.000131	0.00135	CcSEcCtD
Mefenamic acid—Paraesthesia—Epirubicin—bone cancer	0.000131	0.00135	CcSEcCtD
Mefenamic acid—Dyspnoea—Epirubicin—bone cancer	0.00013	0.00134	CcSEcCtD
Mefenamic acid—Somnolence—Epirubicin—bone cancer	0.00013	0.00133	CcSEcCtD
Mefenamic acid—AKR1C1—Signaling Pathways—GRM1—bone cancer	0.000129	0.00239	CbGpPWpGaD
Mefenamic acid—Anorexia—Doxorubicin—bone cancer	0.000129	0.00132	CcSEcCtD
Mefenamic acid—Feeling abnormal—Methotrexate—bone cancer	0.000128	0.00132	CcSEcCtD
Mefenamic acid—Dyspepsia—Epirubicin—bone cancer	0.000128	0.00132	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Methotrexate—bone cancer	0.000127	0.00131	CcSEcCtD
Mefenamic acid—AKR1C1—Disease—DHFR—bone cancer	0.000127	0.00235	CbGpPWpGaD
Mefenamic acid—PTGS2—C-MYB transcription factor network—KIT—bone cancer	0.000127	0.00235	CbGpPWpGaD
Mefenamic acid—Decreased appetite—Epirubicin—bone cancer	0.000127	0.0013	CcSEcCtD
Mefenamic acid—Hypotension—Doxorubicin—bone cancer	0.000126	0.0013	CcSEcCtD
Mefenamic acid—Gastrointestinal disorder—Epirubicin—bone cancer	0.000126	0.00129	CcSEcCtD
Mefenamic acid—Constipation—Epirubicin—bone cancer	0.000125	0.00128	CcSEcCtD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000124	0.00229	CbGpPWpGaD
Mefenamic acid—Urticaria—Methotrexate—bone cancer	0.000124	0.00127	CcSEcCtD
Mefenamic acid—Body temperature increased—Methotrexate—bone cancer	0.000123	0.00127	CcSEcCtD
Mefenamic acid—Abdominal pain—Methotrexate—bone cancer	0.000123	0.00127	CcSEcCtD
Mefenamic acid—AKR1C2—Metabolism—CYP3A4—bone cancer	0.000123	0.00227	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	0.000122	0.00226	CbGpPWpGaD
Mefenamic acid—Insomnia—Doxorubicin—bone cancer	0.000122	0.00125	CcSEcCtD
Mefenamic acid—Paraesthesia—Doxorubicin—bone cancer	0.000121	0.00124	CcSEcCtD
Mefenamic acid—Dyspnoea—Doxorubicin—bone cancer	0.00012	0.00124	CcSEcCtD
Mefenamic acid—Feeling abnormal—Epirubicin—bone cancer	0.00012	0.00123	CcSEcCtD
Mefenamic acid—Somnolence—Doxorubicin—bone cancer	0.00012	0.00123	CcSEcCtD
Mefenamic acid—Gastrointestinal pain—Epirubicin—bone cancer	0.000119	0.00122	CcSEcCtD
Mefenamic acid—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	0.000119	0.0022	CbGpPWpGaD
Mefenamic acid—Dyspepsia—Doxorubicin—bone cancer	0.000119	0.00122	CcSEcCtD
Mefenamic acid—Decreased appetite—Doxorubicin—bone cancer	0.000117	0.0012	CcSEcCtD
Mefenamic acid—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	0.000117	0.00216	CbGpPWpGaD
Mefenamic acid—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000116	0.0012	CcSEcCtD
Mefenamic acid—Urticaria—Epirubicin—bone cancer	0.000116	0.00119	CcSEcCtD
Mefenamic acid—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	0.000116	0.00214	CbGpPWpGaD
Mefenamic acid—Constipation—Doxorubicin—bone cancer	0.000115	0.00119	CcSEcCtD
Mefenamic acid—Body temperature increased—Epirubicin—bone cancer	0.000115	0.00118	CcSEcCtD
Mefenamic acid—Abdominal pain—Epirubicin—bone cancer	0.000115	0.00118	CcSEcCtD
Mefenamic acid—AKR1C1—Metabolism—ENO2—bone cancer	0.000115	0.00212	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	0.000113	0.00208	CbGpPWpGaD
Mefenamic acid—Asthenia—Methotrexate—bone cancer	0.000112	0.00115	CcSEcCtD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	0.000111	0.00206	CbGpPWpGaD
Mefenamic acid—Feeling abnormal—Doxorubicin—bone cancer	0.000111	0.00114	CcSEcCtD
Mefenamic acid—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000111	0.00204	CbGpPWpGaD
Mefenamic acid—Gastrointestinal pain—Doxorubicin—bone cancer	0.00011	0.00113	CcSEcCtD
Mefenamic acid—Pruritus—Methotrexate—bone cancer	0.00011	0.00113	CcSEcCtD
Mefenamic acid—Urticaria—Doxorubicin—bone cancer	0.000107	0.0011	CcSEcCtD
Mefenamic acid—Abdominal pain—Doxorubicin—bone cancer	0.000107	0.0011	CcSEcCtD
Mefenamic acid—Body temperature increased—Doxorubicin—bone cancer	0.000107	0.0011	CcSEcCtD
Mefenamic acid—Diarrhoea—Methotrexate—bone cancer	0.000107	0.0011	CcSEcCtD
Mefenamic acid—AKR1C1—Metabolism—DHFR—bone cancer	0.000106	0.00197	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—GSTP1—bone cancer	0.000105	0.00194	CbGpPWpGaD
Mefenamic acid—Asthenia—Epirubicin—bone cancer	0.000105	0.00107	CcSEcCtD
Mefenamic acid—Pruritus—Epirubicin—bone cancer	0.000103	0.00106	CcSEcCtD
Mefenamic acid—Dizziness—Methotrexate—bone cancer	0.000103	0.00106	CcSEcCtD
Mefenamic acid—PTGS2—Spinal Cord Injury—CDK4—bone cancer	0.000103	0.0019	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—RGS1—bone cancer	0.0001	0.00185	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—GRM4—bone cancer	0.0001	0.00185	CbGpPWpGaD
Mefenamic acid—CYP2C8—Biological oxidations—CYP3A4—bone cancer	9.98e-05	0.00184	CbGpPWpGaD
Mefenamic acid—Diarrhoea—Epirubicin—bone cancer	9.97e-05	0.00102	CcSEcCtD
Mefenamic acid—AKR1C1—Metabolism—GNA11—bone cancer	9.95e-05	0.00184	CbGpPWpGaD
Mefenamic acid—Vomiting—Methotrexate—bone cancer	9.9e-05	0.00102	CcSEcCtD
Mefenamic acid—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	9.84e-05	0.00182	CbGpPWpGaD
Mefenamic acid—Rash—Methotrexate—bone cancer	9.82e-05	0.00101	CcSEcCtD
Mefenamic acid—Dermatitis—Methotrexate—bone cancer	9.81e-05	0.00101	CcSEcCtD
Mefenamic acid—Headache—Methotrexate—bone cancer	9.76e-05	0.001	CcSEcCtD
Mefenamic acid—Asthenia—Doxorubicin—bone cancer	9.68e-05	0.000995	CcSEcCtD
Mefenamic acid—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	9.67e-05	0.00179	CbGpPWpGaD
Mefenamic acid—Dizziness—Epirubicin—bone cancer	9.64e-05	0.000991	CcSEcCtD
Mefenamic acid—Pruritus—Doxorubicin—bone cancer	9.54e-05	0.000981	CcSEcCtD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	9.43e-05	0.00174	CbGpPWpGaD
Mefenamic acid—Vomiting—Epirubicin—bone cancer	9.27e-05	0.000952	CcSEcCtD
Mefenamic acid—PTGS1—Metabolism—NDUFA12—bone cancer	9.26e-05	0.00171	CbGpPWpGaD
Mefenamic acid—Nausea—Methotrexate—bone cancer	9.25e-05	0.000951	CcSEcCtD
Mefenamic acid—Diarrhoea—Doxorubicin—bone cancer	9.23e-05	0.000948	CcSEcCtD
Mefenamic acid—AKR1C3—Disease—ENO2—bone cancer	9.22e-05	0.0017	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—TGFBR2—bone cancer	9.21e-05	0.0017	CbGpPWpGaD
Mefenamic acid—Rash—Epirubicin—bone cancer	9.19e-05	0.000945	CcSEcCtD
Mefenamic acid—Dermatitis—Epirubicin—bone cancer	9.18e-05	0.000944	CcSEcCtD
Mefenamic acid—Headache—Epirubicin—bone cancer	9.13e-05	0.000938	CcSEcCtD
Mefenamic acid—AKR1C1—Signaling Pathways—SMO—bone cancer	9.1e-05	0.00168	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—CYP3A4—bone cancer	9.02e-05	0.00167	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	8.98e-05	0.00166	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—RB1—bone cancer	8.94e-05	0.00165	CbGpPWpGaD
Mefenamic acid—Dizziness—Doxorubicin—bone cancer	8.92e-05	0.000917	CcSEcCtD
Mefenamic acid—AKR1C3—Signaling Pathways—GRM1—bone cancer	8.69e-05	0.00161	CbGpPWpGaD
Mefenamic acid—Nausea—Epirubicin—bone cancer	8.66e-05	0.00089	CcSEcCtD
Mefenamic acid—Vomiting—Doxorubicin—bone cancer	8.58e-05	0.000881	CcSEcCtD
Mefenamic acid—AKR1C3—Disease—DHFR—bone cancer	8.55e-05	0.00158	CbGpPWpGaD
Mefenamic acid—CYP2C8—Biological oxidations—GSTP1—bone cancer	8.54e-05	0.00158	CbGpPWpGaD
Mefenamic acid—Rash—Doxorubicin—bone cancer	8.5e-05	0.000874	CcSEcCtD
Mefenamic acid—Dermatitis—Doxorubicin—bone cancer	8.5e-05	0.000873	CcSEcCtD
Mefenamic acid—Headache—Doxorubicin—bone cancer	8.45e-05	0.000868	CcSEcCtD
Mefenamic acid—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	8.42e-05	0.00156	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—GNA11—bone cancer	8.32e-05	0.00154	CbGpPWpGaD
Mefenamic acid—CYP2C9—Biological oxidations—CYP3A4—bone cancer	8.12e-05	0.0015	CbGpPWpGaD
Mefenamic acid—Nausea—Doxorubicin—bone cancer	8.01e-05	0.000823	CcSEcCtD
Mefenamic acid—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	8.01e-05	0.00148	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—ATF1—bone cancer	7.74e-05	0.00143	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—ENO2—bone cancer	7.72e-05	0.00143	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—GSTP1—bone cancer	7.72e-05	0.00143	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—NT5C3A—bone cancer	7.67e-05	0.00142	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—IL3—bone cancer	7.54e-05	0.00139	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NDUFA12—bone cancer	7.35e-05	0.00136	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—DHFR—bone cancer	7.16e-05	0.00132	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.99e-05	0.00129	CbGpPWpGaD
Mefenamic acid—CYP2C9—Biological oxidations—GSTP1—bone cancer	6.95e-05	0.00128	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	6.85e-05	0.00127	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—GNA11—bone cancer	6.7e-05	0.00124	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TGFBR2—bone cancer	6.45e-05	0.00119	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—MMP9—bone cancer	6.44e-05	0.00119	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—KIT—bone cancer	6.29e-05	0.00116	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—TGFBR2—bone cancer	6.2e-05	0.00115	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—SMO—bone cancer	6.12e-05	0.00113	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—NT5C3A—bone cancer	6.09e-05	0.00113	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—CYP3A4—bone cancer	6.07e-05	0.00112	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—IGF1R—bone cancer	6.07e-05	0.00112	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	6.04e-05	0.00112	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NDUFA12—bone cancer	5.98e-05	0.00111	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—BRAF—bone cancer	5.91e-05	0.00109	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—GNA11—bone cancer	5.6e-05	0.00103	CbGpPWpGaD
Mefenamic acid—AKR1C2—Metabolism—PTGS2—bone cancer	5.45e-05	0.00101	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—EGFR—bone cancer	5.21e-05	0.000962	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—ATF1—bone cancer	5.21e-05	0.000962	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—GSTP1—bone cancer	5.19e-05	0.000959	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	5.18e-05	0.000958	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—IL3—bone cancer	5.08e-05	0.000938	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—NT5C3A—bone cancer	4.96e-05	0.000916	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—MDM2—bone cancer	4.95e-05	0.000915	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NDUFA12—bone cancer	4.87e-05	0.0009	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—PTGS2—bone cancer	4.77e-05	0.000882	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	4.51e-05	0.000833	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—KIT—bone cancer	4.4e-05	0.000813	CbGpPWpGaD
Mefenamic acid—PTGS2—Spinal Cord Injury—TP53—bone cancer	4.37e-05	0.000808	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TGFBR2—bone cancer	4.34e-05	0.000802	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—KIT—bone cancer	4.23e-05	0.000782	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—BRAF—bone cancer	4.14e-05	0.000765	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—IGF1R—bone cancer	4.08e-05	0.000755	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—NT5C3A—bone cancer	4.03e-05	0.000745	CbGpPWpGaD
Mefenamic acid—AKR1C1—Metabolism—PTGS2—bone cancer	4e-05	0.000739	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—BRAF—bone cancer	3.98e-05	0.000735	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.54e-05	0.000655	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—MDM2—bone cancer	3.47e-05	0.000641	CbGpPWpGaD
Mefenamic acid—AKR1C1—Disease—EGFR—bone cancer	3.38e-05	0.000625	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—ENO2—bone cancer	3.36e-05	0.000621	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—MDM2—bone cancer	3.33e-05	0.000616	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—PTGS2—bone cancer	3.21e-05	0.000593	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—ENO2—bone cancer	3.19e-05	0.000589	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—DHFR—bone cancer	3.12e-05	0.000576	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—JUN—bone cancer	3.01e-05	0.000557	CbGpPWpGaD
Mefenamic acid—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.97e-05	0.00055	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—KIT—bone cancer	2.96e-05	0.000547	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—DHFR—bone cancer	2.96e-05	0.000546	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—MMP9—bone cancer	2.93e-05	0.000542	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GNA11—bone cancer	2.91e-05	0.000539	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—BRAF—bone cancer	2.78e-05	0.000515	CbGpPWpGaD
Mefenamic acid—AKR1C3—Metabolism—PTGS2—bone cancer	2.69e-05	0.000497	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—ENO2—bone cancer	2.67e-05	0.000493	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—CYP3A4—bone cancer	2.64e-05	0.000488	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.63e-05	0.000486	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—DHFR—bone cancer	2.48e-05	0.000457	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—EGFR—bone cancer	2.37e-05	0.000438	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MDM2—bone cancer	2.33e-05	0.000431	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GNA11—bone cancer	2.31e-05	0.000428	CbGpPWpGaD
Mefenamic acid—AKR1C3—Disease—EGFR—bone cancer	2.28e-05	0.000421	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—GSTP1—bone cancer	2.26e-05	0.000418	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—ENO2—bone cancer	2.17e-05	0.000401	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—TGFBR2—bone cancer	2.14e-05	0.000396	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—CYP3A4—bone cancer	2.1e-05	0.000388	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—JUN—bone cancer	2.03e-05	0.000375	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—DHFR—bone cancer	2.01e-05	0.000372	CbGpPWpGaD
Mefenamic acid—AKR1C1—Signaling Pathways—TP53—bone cancer	1.99e-05	0.000368	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—MMP9—bone cancer	1.97e-05	0.000365	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GNA11—bone cancer	1.88e-05	0.000348	CbGpPWpGaD
Mefenamic acid—PTGS2—Metabolism—GSTP1—bone cancer	1.79e-05	0.000332	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—ENO2—bone cancer	1.77e-05	0.000327	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—CYP3A4—bone cancer	1.71e-05	0.000315	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.7e-05	0.000314	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—DHFR—bone cancer	1.64e-05	0.000303	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—EGFR—bone cancer	1.59e-05	0.000295	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GNA11—bone cancer	1.53e-05	0.000283	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—KIT—bone cancer	1.46e-05	0.00027	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—GSTP1—bone cancer	1.46e-05	0.00027	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—CYP3A4—bone cancer	1.39e-05	0.000257	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.38e-05	0.000255	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—BRAF—bone cancer	1.37e-05	0.000254	CbGpPWpGaD
Mefenamic acid—AKR1C3—Signaling Pathways—TP53—bone cancer	1.34e-05	0.000247	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—GSTP1—bone cancer	1.19e-05	0.00022	CbGpPWpGaD
Mefenamic acid—PTGS1—Metabolism—PTGS2—bone cancer	1.17e-05	0.000216	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—MDM2—bone cancer	1.15e-05	0.000213	CbGpPWpGaD
Mefenamic acid—PTGS2—Disease—EGFR—bone cancer	7.87e-06	0.000145	CbGpPWpGaD
Mefenamic acid—CYP2C8—Metabolism—PTGS2—bone cancer	7.56e-06	0.00014	CbGpPWpGaD
Mefenamic acid—CYP2C9—Metabolism—PTGS2—bone cancer	6.15e-06	0.000114	CbGpPWpGaD
